ImmunoGen lines up FDA filing as antibody-drug conjugate shrinks tumors in pivotal trial

After toiling for 40 years, ImmunoGen can now see the potential approval of its first wholly owned oncology drug on the horizon. The biotech is preparing to submit mirvetuximab soravtansine for approval after showing the antibody-drug conjugate (ADC) shrank ovarian tumors.